US-based TearScience has released LipiScan, a dedicated high-definition (HD) imager to test meibomian glands for treatment of meibomian gland dysfunction (MGD).
Claimed to be the first of its kind, LipiScan is based on patented dynamic meibomian imaging (DMI) technology to generate high-definition images of meibomian glands.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MGD accounts being a prevalent chronic, obstructive and progressive disease that affects the tear film, visual performance and ocular comfort.
TearScience president and CEO Joseph Boorady said: "Amid growing recognition of MGD as a core root cause of fluctuating vision and discomfort, we saw the need for a technology to make assessment of meibomian glands routine.
"We are proud to transform care and lead innovation for MGD. LipiScan allows ECPs to evaluate meibomian gland structure in all patients.
"Because it is largely caused by modern lifestyles, many patients are at risk for MGD including surgical, contact lens and dry eye patients."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new LipiScan dynamic meibomian imager (DMI) is an ophthalmic imaging device, which is used by physicians in adult patients to generate, archive and modify distinguishing images of meibomian gland structure.
The company noted that it will market LipiScan in an affordable price to enable the physicians to evaluate meibomian gland structure during routine workups in any practice setting.
